540694.BO Stock Analysis
54
Uncovered
ANG Lifesciences India Ltd is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
ANG Lifesciences India Ltd. engages in the manufacture and marketing of finished pharmaceutical formulations in a form of sterile dry powder for injection vials. The company is headquartered in Amritsar, Punjab and currently employs 545 full-time employees. The company went IPO on 2017-09-08. The firm is engaged in the business of manufacturing and marketing of finished pharmaceutical formulations in a dosage form of sterile dry powder injection vials. The company operates in two segments, namely pharmaceuticals and printing and packagings. The firm's products portfolio includes various products comprising therapeutic categories, such as Antibiotics, Antiviral, Antimalarial, Antiulcer, Carbapenem, Corticosteroid, Penicillin and Beta Lactamase Inhibitor. The company is engaged in the business of manufacturing and sales of finished pharmaceutical formulations in a dosage form of Dry Powder Injection Vials, Liquid Injections Vials, Ampoules, PFS, Hard Gelatin Capsules, Tablets, Soft Gelatin Capsules, Dry Syrups, Liquid Syru ps and Suspension, and Lotions, among others. The firm's subsidiaries include ANG Lifesciences India Limited and Mansa Prints and Publishers Limited.